Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 7/20 | 0.44 |
| ▸ | FLT3 | P36888 | 5/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021965 | 0.91 | ADORA3 (0.43) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3026215 | 0.91 | ADORA3 (0.43) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3021971 | 0.91 | ADORA3 (0.43) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3015203 | 0.91 | MAPKAPK2 (0.47) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3020113 | 0.89 | FLT3 (0.42) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3020115 | 0.89 | FLT3 (0.42) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3025252 | 0.89 | CDK2 (0.47) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3025258 | 0.89 | CDK2 (0.47) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3022048 | 0.88 | FLT3 (0.45) | MAPK8CDK2FLT3CCNE1MAPKAPK2 | |
| SCHEMBL3022042 | 0.88 | FLT3 (0.45) | MAPK8CDK2FLT3CCNE1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | MAPK8 84/4885CDK2 40/4885FLT3 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.